A Novel Antagonistic CD73 Antibody for Inhibition of the Immunosuppressive Adenosine Pathway

Despite some impressive clinical results with immune checkpoint inhibitors, the majority of patients with cancer do not respond to these agents, in part due to immunosuppressive mechanisms in the tumor microenvironment. High levels of adenosine in tumors can suppress immune cell function, and strate...

Descripción completa

Detalles Bibliográficos
Autores principales: Wurm, Melanie, Schaaf, Otmar, Reutner, Katharina, Ganesan, Rajkumar, Mostböck, Sven, Pelster, Christina, Böttcher, Jark, de Andrade Pereira, Bruna, Taubert, Christina, Alt, Isabella, Serna, Garazi, Auguste, Aurelie, Stadermann, Kai B., Delic, Denis, Han, Fei, Capdevila, Jaume, Nuciforo, Paolo G., Kroe-Barrett, Rachel, Adam, Paul J., Vogt, Anne B., Hofmann, Irmgard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Large Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398120/
https://www.ncbi.nlm.nih.gov/pubmed/34482286
http://dx.doi.org/10.1158/1535-7163.MCT-21-0107

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398120/
https://www.ncbi.nlm.nih.gov/pubmed/34482286
http://dx.doi.org/10.1158/1535-7163.MCT-21-0107

Ejemplares similares